Kim Haeyoung, Pyo Hongryull, Park Hee Chul, Lim Do Hoon, Yu Jeong Il, Park Won, Ahn Yong Chan, Choi Doo Ho, Oh Dongryul, Noh Jae Myoung, Cho Won Kyung, Yoo Gyu Sang, Jung Sang Hoon, Kim Eun-Sang, Lee Sun-Ho, Park Se-Jun, Lee Chong-Suh
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Bone Oncol. 2021 May 1;28:100368. doi: 10.1016/j.jbo.2021.100368. eCollection 2021 Jun.
This analysis was performed to evaluate the incidence of vertebral compression fracture (VCF) and determine the contributing factors for VCF in patients undergoing single-fraction stereotactic body radiotherapy (SBRT) for spinal bone metastases (SBM).
A retrospective review of medical records was conducted for patients undergoing SBRT for SBM at our institution between January 2010 and December 2018. Patients who had undergone neither pre-SBRT surgical excision nor post-SBRT prophylactic fixation were included. The effects of clinical and dosimetric parameters were analyzed with respect to VCF risk. The following dosimietric parameters of the planning target volume (PTV) were calculated: mean/minimum/maximum dose, radiation dose to 10-90% volume, and irradiated volume receiving more than 10-25 Gy (PTV_V).
Among 163 patients (179 vertebrae), 21 (12.8%) experienced VCF. The 1-year and 2-year VCF rates were 12.1% and 13.2%, respectively. Among dosimetric parameters, PTV_V15 Gy was the most significant for VCF prediction. In a univariate analysis, breast or prostate primary, no vertebral body collapse, and PTV_V ≤42 cm were significantly associated with a lower incidence rate of VCF. In a multivariate analysis, PTV_V was the only significant factor for VCF risk. The 1-year VCF rate was 3.8% in patients with PTV_V ≤42 cm, while it was 22.1% in those with PTV_V > 42 cm ( < 0.01).
SBRT-related VCF was found in 12% of patients in our institution. The PTV_V is a significant factor for VCF prediction.
进行此项分析以评估椎体压缩性骨折(VCF)的发生率,并确定接受单次立体定向体部放疗(SBRT)治疗脊柱骨转移瘤(SBM)患者发生VCF的相关因素。
对2010年1月至2018年12月期间在本机构接受SBRT治疗SBM的患者病历进行回顾性分析。纳入未接受SBRT前手术切除或SBRT后预防性内固定的患者。分析临床和剂量学参数对VCF风险的影响。计算计划靶体积(PTV)的以下剂量学参数:平均/最小/最大剂量、10 - 90%体积的辐射剂量以及接受超过10 - 25 Gy的照射体积(PTV_V)。
163例患者(179个椎体)中,21例(12.8%)发生VCF。1年和2年VCF发生率分别为12.1%和13.2%。在剂量学参数中,PTV_V15 Gy对VCF预测最为显著。单因素分析中,乳腺癌或前列腺癌原发、无椎体塌陷以及PTV_V≤42 cm与较低的VCF发生率显著相关。多因素分析中,PTV_V是VCF风险的唯一显著因素。PTV_V≤42 cm的患者1年VCF发生率为3.8%,而PTV_V > 42 cm的患者为22.1%(<0.01)。
本机构12%的患者发生了与SBRT相关的VCF。PTV_V是VCF预测的重要因素。